Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University Hospital, Leipzig, Germany (I.G., S.F., A.E., S.N., M.M.A.-D., R.R., J.M., D.G., R.B., S.K., B.I., K.S.).
Medical Laboratories, Faculty of Health Sciences, American University of Madaba, Amman, Jordan (M.M.A.-D.).
Circ Res. 2021 Feb 19;128(4):513-529. doi: 10.1161/CIRCRESAHA.120.317219. Epub 2020 Dec 23.
While thrombin is the key protease in thrombus formation, other coagulation proteases, such as fXa (factor Xa) or aPC (activated protein C), independently modulate intracellular signaling via partially distinct receptors.
To study the differential effects of fXa or fIIa (factor IIa) inhibition on gene expression and inflammation in myocardial ischemia-reperfusion injury.
Mice were treated with a direct fIIa inhibitor (fIIai) or direct fXa inhibitor (fXai) at doses that induced comparable anticoagulant effects ex vivo and in vivo (tail-bleeding assay and FeCl-induced thrombosis). Myocardial ischemia-reperfusion injury was induced via left anterior descending ligation. We determined infarct size and in vivo aPC generation, analyzed gene expression by RNA sequencing, and performed immunoblotting and ELISA. The signaling-only 3K3A-aPC variant and inhibitory antibodies that blocked all or only the anticoagulant function of aPC were used to determine the role of aPC. Doses of fIIai and fXai that induced comparable anticoagulant effects resulted in a comparable reduction in infarct size. However, unbiased gene expression analyses revealed marked differences, including pathways related to sterile inflammation and inflammasome regulation. fXai but not fIIai inhibited sterile inflammation by reducing the expression of proinflammatory cytokines (IL [interleukin]-1β, IL-6, and TNFα [tumor necrosis factor alpha]), as well as NF-κB (nuclear factor kappa B) and inflammasome activation. This anti-inflammatory effect was associated with reduced myocardial fibrosis 28 days post-myocardial ischemia-reperfusion injury. Mechanistically, in vivo aPC generation was higher with fXai than with fIIai. Inhibition of the anticoagulant and signaling properties of aPC abolished the anti-inflammatory effect associated with fXai, while inhibiting only the anticoagulant function of aPC had no effect. Combining 3K3A-aPC with fIIai reduced the inflammatory response, mimicking the fXai-associated effect.
We showed that specific inhibition of coagulation via direct oral anticoagulants had differential effects on gene expression and inflammation, despite comparable anticoagulant effects and infarct sizes. Targeting individual coagulation proteases induces specific cellular responses unrelated to their anticoagulant effect.
虽然凝血酶是血栓形成的关键蛋白酶,但其他凝血蛋白酶,如 fXa(因子 Xa)或 aPC(活化蛋白 C),通过部分不同的受体独立地调节细胞内信号转导。
研究 fXa 或 fIIa(因子 IIa)抑制对心肌缺血再灌注损伤中基因表达和炎症的差异影响。
在体外和体内(尾巴出血试验和 FeCl 诱导的血栓形成)用直接 fIIa 抑制剂(fIIai)或直接 fXa 抑制剂(fXai)以诱导相当的抗凝效果的剂量处理小鼠。通过左前降支结扎诱导心肌缺血再灌注损伤。我们确定了梗塞面积和体内 aPC 的产生,通过 RNA 测序分析基因表达,并进行免疫印迹和 ELISA。使用仅信号的 3K3A-aPC 变体和阻断 aPC 的抗凝功能的抑制性抗体来确定 aPC 的作用。诱导相当的抗凝效果的 fIIai 和 fXai 剂量导致梗塞面积相当的减少。然而,无偏基因表达分析显示出明显的差异,包括与无菌炎症和炎症小体调节相关的途径。fXai 而不是 fIIai 通过降低促炎细胞因子(IL [白细胞介素]-1β、IL-6 和 TNFα[肿瘤坏死因子 alpha])以及 NF-κB(核因子 kappa B)和炎症小体激活的表达来抑制无菌炎症。这种抗炎作用与心肌缺血再灌注损伤后 28 天的心肌纤维化减少有关。在机制上,fXai 比 fIIai 体内 aPC 的产生更高。抑制 aPC 的抗凝和信号特性消除了与 fXai 相关的抗炎作用,而仅抑制 aPC 的抗凝功能则没有作用。将 3K3A-aPC 与 fIIai 结合可减少炎症反应,模拟 fXai 相关作用。
我们表明,尽管具有相当的抗凝效果和梗塞面积,通过直接口服抗凝剂特异性抑制凝血对基因表达和炎症具有不同的影响。靶向单个凝血蛋白酶会引起与抗凝作用无关的特定细胞反应。